Sodium-glucose cotransporter-2 (SGLT2) inhibitor drugs for type 2 diabetes rank among the top safety concerns of the year, according to a new report by the Institute for Safe Medication Practices (ISMP).
In its most recent QuarterWatch (June 2016), a drug safety publication, the ISMP noted that these new drugs are spreading rapidly into clinical practice, with more than 2 million prescriptions by late 2015, but have unanswered questions about long-term clinical benefits and